| Title | AT1-receptor blocker-based combination therapy in hypertension. | | Author(s) | Trenkwalder P | | Institution | Ludwig Maximilian University Munich, Starnberg, Germany. Peter.Trenkwalder@t-online.de | | Source | Blood Press Suppl 2001; (3):18-25. | | MeSH | Antihypertensive Agents
Benzothiadiazines
Diuretics
Drug Interactions
Drug Therapy, Combination
Humans
Hypertension
Receptor, Angiotensin, Type 1
Receptors, Angiotensin
Sodium Chloride Symporter Inhibitors
| | Abstract | Despite an increase in the number of patients treated for hypertension, blood pressure control is achieved in a minority of patients. The use of rational, well-tolerated combination regimens with complementary modes of action, such as an AT1-receptor blocker administered with a low dose of a thiazide diuretic, provides an effective and well-tolerated management strategy for patients who require more than monotherapy to control blood pressure. In clinical trials in patients with mild-to-moderate hypertension, a newly available combination of candesartan cilexetil-hydrochlorothiazide (HCT) 16/12.5 mg was significantly more effective than either monotherapy. This combination was also more effective than losartan-HCT 50/12.5 mg in two double-blind, randomized studies in patients with mild, moderate or severe hypertension. Furthermore, the antihypertensive efficacy of candesartan cilexetil-HCT was evident at up to 48 h following the last dose, while the effect of losartan-HCT declined rapidly during this period. Thus, the new fixed-dose AT1-receptor blocker/diuretic combination, candesartan cilexetil-HCT 16/12.5 mg combines enhanced efficacy with excellent tolerability and sets a new standard for the treatment of hypertension requiring more than monotherapy. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 11683473 |
|
